Flamma Opens New cGMP Plant in China
The Flamma Group, a Contract Development and Manufacturing Organization (CDMO), recently celebrated the grand opening of a new cGMP plant in Dalian, China.
Flamma
The Evolution of the CDMO Industry
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine. CHEManager asked executives and industry experts from a broad range of CDMOs to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.
Expert Statement: Kenneth N. Drew, Flamma
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Flamma Invests $200 Million to Expand CDMO Capabilities
Italian CDMO Flamma Group intends to invest $200 million over the next three years to expand its capabilities to meet growing market demand.
Flamma Boosts API Manufacturing with Third Site
Flamma Group, a company specializing in producing and commercializing small molecule APIs for the life science industry, as well as being a CDMO for new chemical entities and late-stage intermediates, is to acquire a third manufacturing site in Italy as of April.
Expert Interview: GianMarco Negrisoli, Flamma
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
